TNF and inflammatory bowel disease: Differences in the odds of hospitalization or death among those who received TNF inhibitor monotherapy vs a TNF inhibitor in combination with methotrexate therapy were not statistically significant in the registry-specific analyses (GRA: OR, 1.20 [95% CI, 0.80-1.79; P = .38]; SECURE-IBD: OR, 1.59 [95% CI, 0.76-3.34; P = .22]) or the pooled analysis (OR, 1.18; 95% CI, 0.85-1.63; P = .33).